Format

Send to

Choose Destination
Aesthet Surg J. 2018 Jul 31. doi: 10.1093/asj/sjy185. [Epub ahead of print]

Safety and Efficacy of a Scar Cream Consisting of Highly Selective Growth Factors Within a Silicone Cream Matrix: A Double-Blinded, Randomized, Multicenter Study.

Author information

1
Keck School of Medicine, University of Southern California, Los Angeles, CA.
2
Private Oculoplastic Surgery Practice in Los Angeles, CA.
3
Department of Plastic Surgery, UCLA David Geffen School of Medicine, Los Angeles, CA.
4
Dermatology Service, Memorial Sloan Kettering Center, New York, NY.
5
Department of Plastic Surgery, Loma Linda University Medical Center, Loma Linda, CA.

Abstract

Background:

Several growth factors and hyaluronic acid (HA) are implicated in fetal scarless healing. Whether these factors can be applied toward an adult scar to improve scar characteristics is unknown.

Objective:

This study compared the efficacy and safety of SKN2017B, a proprietary topical cream consisting of selective synthetic recombinant human growth factors and HA in a silicone base with a specifically formulated silicone cream for postsurgical scar treatment.

Methods:

In this prospective, randomized, controlled, double-blinded study, unilateral or bilateral facial or truncal scars in adult surgical patients were randomly treated with SKN2017B or silicone cream. Study investigators, study subjects, and 2 independent reviewers assessed improvement in scar characteristics after 4 and 12 weeks of treatment.

Results:

Forty-nine bilateral and 12 unilateral scars in 45 subjects were treated with SKN2017B or silicone. At 12 weeks, investigators rated 74% of scars treated with SKN2017B to have shown overall improvement versus 54% of silicone-treated scars; a 73% relative improvement with SKN2017B (P < 0.0001). Subjects rated a moderate-to-significant improvement in 85% of SKN2017B-treated scars versus 51% of silicone-treated scars, a 67% relative improvement with SKN2017B (P < 0.001). Independent reviewers rated 87% of scars treated with SKN2017B to be better overall versus 1% of scars treated with silicone (P < 0.0001). There were no tolerability issues or adverse reactions with either cream.

Conclusion:

SKN2017B consisting of highly selective growth factors within a silicone cream matrix is well tolerated and effective for surgical scar management.

PMID:
30084900
DOI:
10.1093/asj/sjy185

Supplemental Content

Full text links

Icon for Silverchair Information Systems
Loading ...
Support Center